Serious fatal and nonfatal non-AIDS-defining illnesses in Europe

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 262-270

  Mocroft, Amanda ^a   Reiss, Peter ^b   Gasiorowski, Jacek ^c   Ledergerber, Bruno ^d   Kowalska, Justyna ^e   Chiesi, Antonio ^f   Gatell, Jose ^g   Rakhmanova, Aza ^h   Johnson, Margaret ⁱ   Kirk, Ole ^e   Lundgren, Jens ^e,j  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h Medical Academy Botkin Hospital   (Russian Federation)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j Rigshospitalet   (Denmark)

more..

Author keywords

AIDS defining illnesses; CD4; HIV; Morbidity; Mortality; Non AIDS defining illnesses

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DEATH; DIABETES MELLITUS; ESOPHAGUS CANDIDIASIS; EUROPE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INCIDENCE; INSULIN TREATMENT; KIDNEY FAILURE; LIVER FAILURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; WASTING SYNDROME; AGE; COMPLICATION; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; KAPLAN MEIER METHOD; MORTALITY; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGY; EUROPE; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MORTALITY; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; KAPLAN-MEIER ESTIMATE;

EID: 77957305505     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e9be6b     Document Type: Article

References (56)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994- 1998: the EuroSIDA study. Lancet. 2000;356:291-296.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003; 362:22-29.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
5. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409-2418.
6. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
7. Smith CJ, Olsen CH, Mocroft A, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS. 2008;22:47-56.
8. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143-2153.
9. Smith CJ, Mocroft A, Lundgren JD. Incidence of pancreatitis in HIVinfected patients, and the association with antiretroviral therapy. AIDS. 2008;22:997-998. (Pubitemid 351652255)
10. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.
11. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
12. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548-1559.
13. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
14. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
15. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13:943-950.
16. Mocroft A, Sterne JA, Egger M, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009;48:1138-1151.
17. Moore RD, Gebo KA, Lucas GM, et al. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis. 2008;47: 1102-1104.
18. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22: 841-848.
19. Lundgren JD, Babiker A, El-SadrW, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197:1145-1155.
20. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
21. Reekie J, Mocroft A, Engsig F, et al. Relationship between current level of immunodeficiency and non-AIDS defining malignancies. Cancer. [Epub ahead of Print, 26 July 2010].
22. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19:2117-2125.
23. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol. 2009;10: 1152-1159.
24. Szczech LA, Gange SJ, van der HC, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195-202.
25. Krawczyk CS, Holmberg SD, Moorman AC, et al. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS. 2004;18: 2171-2178.
26. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177-187.
27. Fontas E, van LF, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189: 1056-1074.
28. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-642.
29. Zangerle R, Sarcletti M, Gallati H, et al. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149-1156.
30. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292:191-201.
31. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviralnaive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55: 800-804.
32. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717-1721.
33. Podlekareva D, Mocroft A, Dragsted UB, et al. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: A EuroSIDA study. J Infect Dis. 2006;194:633-641.
34. Bofill M, Janossy G, Lee CA, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol. 1992;88:243-252.
35. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13:959-967.
36. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91:301-308.
37. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38:1454-1463.
38. Sharma S, Gage BF, Deych E, et al. Anemia: An independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J. 2009;157:1057-1063.
39. Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis. 2009;16:131-142.
40. Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev. 2006;32(Suppl 2):S1-S3.
41. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393. (Pubitemid 36159355)
42. Mourad JJ, Le JS. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl. 2008;26:S7-S13.
43. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003;16:101-105. (Pubitemid 37361072)
44. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697-706.
45. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med. 2007;8:547-554.
46. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
47. Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol. 2008;19:844-846.
48. Kowalska J, Mocroft A, Ledergerber B, et al, For the EuroSIDA study group. Estimating AIDS and non-AIDS related deaths for patients with missing death data. Abstract PS6/6. Presented at: 12th European AIDS Clinical Society; November 11-14, 2009; Hamburg, Germany; 2010. Conference Proceeding.
49. Mocroft A, Gatell J, Reiss P, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS. 2004;18:2333-2337.
50. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009; 48:633-639.
51. Causes of death in HIV-1-infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50: 1387-1396
52. Smith C and the D:A:D study group. Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Abstract 145. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada; 2009. Conference Proceeding.
53. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179-187
54. Ferry T, Raffi F, Collin-Filleul F, et al. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr. 2009;51:407-415.
55. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons, Inc; 1987.
56. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. AIDS. 2009;23:41-50.